$496.49
0.54% yesterday
Nasdaq, Apr 28, 10:11 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$496.49
+3.80 0.77% 1M
+20.12 4.22% 6M
+93.79 23.29% YTD
+100.29 25.31% 1Y
+227.85 84.82% 3Y
+239.53 93.22% 5Y
+371.02 295.70% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
+2.65 0.54%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Market capitalization $127.64b
Enterprise Value $123.27b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.22
P/S ratio (TTM) P/S ratio 11.62
P/B ratio (TTM) P/B ratio 7.77
Revenue growth (TTM) Revenue growth 11.64%
Revenue (TTM) Revenue $10.98b
EBIT (operating result TTM) EBIT $-181.60m
Free Cash Flow (TTM) Free Cash Flow $-790.30m
Cash position $6.12b
EPS (TTM) EPS $-2.20
P/E forward 30.68
P/S forward 10.65
EV/Sales forward 10.28
Short interest 1.92%
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

20x Buy
57%
13x Hold
37%
2x Sell
6%

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
57%
Hold
37%
Sell
6%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
10,984 10,984
12% 12%
100%
- Direct Costs 1,531 1,531
21% 21%
14%
9,454 9,454
10% 10%
86%
- Selling and Administrative Expenses 1,259 1,259
32% 32%
11%
- Research and Development Expense 8,171 8,171
123% 123%
74%
24 24
99% 99%
0%
- Depreciation and Amortization 206 206
14% 14%
2%
EBIT (Operating Income) EBIT -182 -182
105% 105%
-2%
Net Profit -536 -536
115% 115%
-5%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Positive
The Motley Fool
about 23 hours ago
Getting dizzy from the stock market's gyrations? Join the club.
Positive
The Motley Fool
6 days ago
Vertex Pharmaceuticals (VRTX 2.72%) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes.
Neutral
Barrons
7 days ago
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today